FAQ on Aditxt Inc.'s ADI-100 Developments and Weekly Update

What is ADI-100?

ADI-100 is the lead therapeutic candidate of Aditxt’s wholly owned subsidiary, Adimune, focusing on novel immune-modulating therapies.

Who discussed the recent progress on ADI-100?

Chief Innovation Officer Dr. Shahrokh Shabahang and Adimune Co-CEO Dr. Friedrich Kapp discussed the progress during Aditxt’s Weekly Update.

Where can I view the full press release about ADI-100 developments?

The full press release can be viewed at https://ibn.fm/SCnWq.

What is Aditxt Inc.’s mission?

Aditxt’s mission is to ‘Make Promising Innovations Possible Together’ by accelerating health innovations through its ecosystem of research institutions, industry partners, and shareholders.

What programs does Aditxt currently operate?

Aditxt currently operates programs focused on immune health and precision health, with plans to introduce additional programs dedicated to public health and women’s health.

What are the conditions for the transactions with Appili Therapeutics and Evofem?

The closing of these transactions is subject to several conditions, including approval by the respective target shareholders and Aditxt raising sufficient capital to fund its obligations at closing.

Where can I find the latest news and updates relating to ADTX?

The latest news and updates are available in the company’s newsroom at https://ibn.fm/ADTX.

What is InvestorWire?

InvestorWire is a specialized communications platform focusing on advanced wire-grade press release syndication for private and public companies and the investment community, part of the Dynamic Brand Portfolio @ IBN.